2 results match your criteria: "Zuckerberg Cancer Institute[Affiliation]"
Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer.
Clin Lung Cancer
November 2023
Division of Medical Oncology and Hematology, Zuckerberg Cancer Institute, Northwell Health, New Hyde Park, NY. Electronic address:
Background: Cancer patients with preexisting autoimmune diseases (AID) have been traditionally excluded from clinical trials of immune checkpoint inhibitors (ICI) due to concerns for toxicity. As indications for ICI expand, more data are needed on the safety and efficacy of ICI treatment in cancer patients with AID.
Methods: We systematically searched for studies consisting of NSCLC, AID, ICI, treatment response, and adverse events.
Kidney and urinary tract involvement in systemic mastocytosis.
Nephrol Dial Transplant
October 2023
Department of Nephrology, Peupliers Private Hospital, Paris, France.
Article Synopsis
- Systemic mastocytosis (SM) is a condition characterized by the abnormal accumulation of mast cells in various tissues, commonly due to mutations in the KIT gene, leading to their survival and proliferation.
- Although the kidneys are rarely directly affected by SM, there are increasing instances of indirect involvement, particularly associated with various kidney conditions such as immune-mediated glomerulonephritis.
- The treatment with new anti-neoplastic agents for advanced SM may lead to kidney dysfunction, and kidney injuries have also been reported in cases where SM is linked to plasma cell disorders.